Arch Therapeutics Will Present at Salomon Bio Investment & Leadership Conference
November 11, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Nov 11, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), today...
Arch Therapeutics Will Present at the 2015 Aegis Capital Growth Conference in Las Vegas, NV October 7-9th, 2015
October 07, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Oct 7, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), today announced...
Arch Therapeutics Obtains Additional Positive Safety Data for AC5 Surgical Hemostatic Device(TM) in Preclinical Toxicity Test of Sensitization
September 08, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Sep 8, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), obtained...
Arch Therapeutics Will Present 17th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2015
August 26, 2015 09:10 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Aug 26, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"),...
Arch Therapeutics Appoints James Sulat to Board of Directors
August 20, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Aug 20, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), has appointed...
Arch Therapeutics Announces Private Placement
July 01, 2015 08:18 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jul 1, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), is pleased...
Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device(TM) in Successful Preclinical Toxicity Test
June 09, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jun 9, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), obtained data...
Arch Therapeutics Initiates Research and Development Collaboration With CURAM Centre for Research in Medical Devices
June 01, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jun 1, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics to Present at 2015 LD MICRO Invitational Conference on June 1
May 18, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - May 18, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics' AC5(TM) Compared Favorably vs. Commercially Available Combination Hemostat in Animal Study
April 16, 2015 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Apr 16, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...